PT  - JOURNAL ARTICLE
AU  - Arantes, Ighor
AU  - Gomes, Marcelo
AU  - Ito, Kimihito
AU  - Sarafim, Sharbilla
AU  - Miyajima, Fábio
AU  - Khouri, Ricardo
AU  - Gräf, Tiago
AU  - Siqueira, Marilda Mendonça
AU  - Resende, Paola Cristina
AU  - Naveca, Felipe Gomes
AU  - Bello, Gonzalo
AU  - ,
TI  - Spatiotemporal dynamics and epidemiological impact of SARS-CoV-2 XBB lineages dissemination in Brazil in 2023
AID  - 10.1101/2023.10.30.23297466
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.10.30.23297466
4099  - http://medrxiv.org/content/early/2023/10/31/2023.10.30.23297466.short
4100  - http://medrxiv.org/content/early/2023/10/31/2023.10.30.23297466.full
AB  - The SARS-CoV-2 XBB is a group of highly immune-evasive lineages of the Omicron VOC that emerged by recombining BA.2-descendent lineages and spread worldwide during 2023. In this study, we combine SARS-CoV-2 genomic data (n = 11,065 sequences) with epidemiological data of Severe Acute Respiratory Infection (SARI) cases collected in Brazil between October 2022 and July 2023 to reconstruct the space-time dynamics and epidemiologic impact of XBB dissemination in the country. Our analyses revealed that the introduction and local emergence of lineages carrying convergent mutations within the Spike protein, especially F486P, F456L, and L455F, propelled the spread of XBB* lineages in Brazil. The average relative instantaneous reproduction numbers of XBB*+F486P, XBB*+F486P+F456L, and XBB*+F486P+ F456L+L455F lineages in Brazil were estimated to be 1.24, 1.33, and 1.48 higher than that of other co-circulating lineages (mainly BQ.1*/BE*), respectively. Despite such a growth advantage, the dissemination of these XBB* lineages had a reduced impact on Brazil’s epidemiological scenario concerning previous Omicron subvariants. The peak number of SARI cases from SARS-CoV-2 during the XBB wave was approximately 90%, 80%, and 70% lower than that observed during the previous BA.1*, BA.5*, and BQ.1* waves, respectively. These findings revealed the emergence of multiple XBB lineages with progressively increasing growth advantage, yet with relatively limited epidemiological impact in Brazil throughout 2023. The XBB*+F486P+F456L+L455F lineages stand out for their heightened transmissibility, warranting close monitoring in the months ahead.Competing Interest StatementThe authors have declared no competing interest.Funding StatementFAPEAM F.G.N. (INICIATIVA AMAZONIA +10 (grant: 01.02.016301.00439/2023-70); Rede Genomica de Vigilancia em Saude - REGESAM); FAPEAM/INOVA FIOCRUZ INOVACAO NA AMAZONIA (Chamada Publica n 04/2022); NPI EXPAND - U.S. Agency for International Development (USAID) implemented by Palladium (7200AA19CA00015). Centers for Disease Control and Prevention (CDC Grant Award 002174); Departamento de Ciencia e Tecnologia (DECIT) of the Brazilian MoH. FAPERJ (Grant number E-26/202.896/2018): G.B. FAPERJ - Fundacao Carlos Chagas Filho de Amparo a Pesquisa do Estado do Rio de Janeiro, Grant SEI-260003/019669/2022: I.A.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Ethics Committee of the Amazonas State University (CAAE: 25430719.6.0000.5016) and by the Ethics Committee of FIOCRUZ (CAAE: 68118417.6.0000.5248), which waived signed informed consent for all participants. All methods followed guidelines and regulations of the Brazilian Ministry of Health.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe findings of this study are based on the analysis of 107,881 SARS-CoV-2 Brazilian genomes collected after January 1st 2022, and submitted to the GISAID database until July 31st 2023, accessible at https://doi.org/10.55876/gis8.231024oa. In our phylogeographic analysis, we additionally downloaded 3,132 global references from the same period available at https://doi.org/10.55876/gis8.231024qe.https://doi.org/10.55876/gis8.231024qehttps://doi.org/10.55876/gis8.231024oa